Arenicin-3

General Information


DRACP ID  DRACP02847

Peptide Name   Arenicin-3

Sequence  GFCWYVCVYRNGVRVCYRRCN

Sequence Length  21

UniProt ID  A0A3F2YLM5 

PubChem CID  Not available

Origin  Arenicola marina

Type  Native peptide

Classification

  

Active ACP Membrane-targeted



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HepG2 Hepatoblastoma Blastoma CC50>300 μg/ml Resazurin assay 24 h 1

Hemolytic Activity  Human erythrocytes: HC10= µg/ml

Normal (non-cancerous) Cytotoxicity  HEK-293: CC50=271 µg/ml; HK-2: CC50=170 µg/ml

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  5V0Y  

Predicted Structure  DRACP02847

Helicity  Not available

Linear/Cyclic  Cyclic

Disulfide/Other Bond  Cys3<--->Cys20; Cys7<--->Cys16

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C115H170N36O27S4

Absent amino acids  ADEHIKLMPQST

Common amino acids  CRV

Mass  297399

Pl  9.01

Basic residues  4

Acidic residues  0

Hydrophobic residues  6

Net charge  4

Boman Index  -4491

Hydrophobicity  -4.76

Aliphatic Index  55.24

Half Life 
  Mammalian: 30 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  10220

Absorbance 280nm  511

Polar residues  11

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 32576824

Title  An amphipathic peptide with antibiotic activity against multidrug-resistant Gram-negative bacteria

Doi 10.1038/s41467-020-16950-x

Year  2020

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPR_7486

DRACP is developed by Dr.Zheng's team.